nodes	percent_of_prediction	percent_of_DWPC	metapath
Afatinib—ERBB2—uterine cancer	0.547	1	CbGaD
Afatinib—ABCG2—Dactinomycin—uterine cancer	0.0489	0.265	CbGbCtD
Afatinib—ABCG2—Carboplatin—uterine cancer	0.0329	0.178	CbGbCtD
Afatinib—ABCG2—Etoposide—uterine cancer	0.0276	0.149	CbGbCtD
Afatinib—ABCB1—Progesterone—uterine cancer	0.0223	0.12	CbGbCtD
Afatinib—ABCG2—Doxorubicin—uterine cancer	0.0188	0.102	CbGbCtD
Afatinib—ABCB1—Dactinomycin—uterine cancer	0.0176	0.0954	CbGbCtD
Afatinib—ABCB1—Etoposide—uterine cancer	0.00996	0.0538	CbGbCtD
Afatinib—ABCB1—Doxorubicin—uterine cancer	0.00679	0.0367	CbGbCtD
Afatinib—ERBB2—oviduct—uterine cancer	0.00641	0.0919	CbGeAlD
Afatinib—ERBB2—exocrine gland—uterine cancer	0.0037	0.0531	CbGeAlD
Afatinib—HIPK4—female reproductive system—uterine cancer	0.00174	0.025	CbGeAlD
Afatinib—ERBB2—epithelium—uterine cancer	0.00161	0.0231	CbGeAlD
Afatinib—ERBB4—epithelium—uterine cancer	0.00161	0.0231	CbGeAlD
Afatinib—ERBB2—smooth muscle tissue—uterine cancer	0.00155	0.0222	CbGeAlD
Afatinib—ERBB2—decidua—uterine cancer	0.00152	0.0218	CbGeAlD
Afatinib—ERBB2—renal system—uterine cancer	0.00149	0.0214	CbGeAlD
Afatinib—DYRK1A—decidua—uterine cancer	0.00146	0.021	CbGeAlD
Afatinib—ERBB2—endometrium—uterine cancer	0.00144	0.0207	CbGeAlD
Afatinib—DYRK1A—renal system—uterine cancer	0.00144	0.0206	CbGeAlD
Afatinib—EPHA6—female reproductive system—uterine cancer	0.00138	0.0198	CbGeAlD
Afatinib—EGFR—uterine cervix—uterine cancer	0.00135	0.0194	CbGeAlD
Afatinib—ERBB2—uterus—uterine cancer	0.00133	0.0191	CbGeAlD
Afatinib—PHKG2—female reproductive system—uterine cancer	0.00133	0.0191	CbGeAlD
Afatinib—Vandetanib—VEGFA—uterine cancer	0.0013	1	CrCbGaD
Afatinib—PHKG2—female gonad—uterine cancer	0.00121	0.0174	CbGeAlD
Afatinib—ERBB4—female reproductive system—uterine cancer	0.00119	0.0171	CbGeAlD
Afatinib—ERBB2—female reproductive system—uterine cancer	0.00119	0.0171	CbGeAlD
Afatinib—IRAK1—uterine cervix—uterine cancer	0.00119	0.0171	CbGeAlD
Afatinib—EGFR—mammalian vulva—uterine cancer	0.00118	0.017	CbGeAlD
Afatinib—LCK—uterine cervix—uterine cancer	0.00116	0.0167	CbGeAlD
Afatinib—IRAK1—smooth muscle tissue—uterine cancer	0.00116	0.0166	CbGeAlD
Afatinib—DYRK1A—female reproductive system—uterine cancer	0.00115	0.0165	CbGeAlD
Afatinib—IRAK1—decidua—uterine cancer	0.00114	0.0163	CbGeAlD
Afatinib—EGFR—uterus—uterine cancer	0.00113	0.0162	CbGeAlD
Afatinib—LCK—decidua—uterine cancer	0.00111	0.0159	CbGeAlD
Afatinib—ERBB2—female gonad—uterine cancer	0.00109	0.0156	CbGeAlD
Afatinib—ERBB4—vagina—uterine cancer	0.00108	0.0155	CbGeAlD
Afatinib—DYRK1A—female gonad—uterine cancer	0.00105	0.015	CbGeAlD
Afatinib—IRAK1—mammalian vulva—uterine cancer	0.00104	0.015	CbGeAlD
Afatinib—BLK—lymph node—uterine cancer	0.00102	0.0146	CbGeAlD
Afatinib—LCK—mammalian vulva—uterine cancer	0.00102	0.0146	CbGeAlD
Afatinib—LCK—uterus—uterine cancer	0.00097	0.0139	CbGeAlD
Afatinib—EGFR—female gonad—uterine cancer	0.000922	0.0132	CbGeAlD
Afatinib—IRAK1—female reproductive system—uterine cancer	0.000894	0.0128	CbGeAlD
Afatinib—ABL1—myometrium—uterine cancer	0.000859	0.0123	CbGeAlD
Afatinib—IRAK1—female gonad—uterine cancer	0.000813	0.0117	CbGeAlD
Afatinib—LCK—female gonad—uterine cancer	0.000793	0.0114	CbGeAlD
Afatinib—LCK—vagina—uterine cancer	0.000788	0.0113	CbGeAlD
Afatinib—PHKG2—lymph node—uterine cancer	0.000777	0.0112	CbGeAlD
Afatinib—ERBB2—lymph node—uterine cancer	0.000699	0.01	CbGeAlD
Afatinib—DYRK1A—lymph node—uterine cancer	0.000673	0.00966	CbGeAlD
Afatinib—ABL1—uterine cervix—uterine cancer	0.000668	0.00959	CbGeAlD
Afatinib—ABL1—smooth muscle tissue—uterine cancer	0.000649	0.00932	CbGeAlD
Afatinib—ABL1—decidua—uterine cancer	0.000637	0.00914	CbGeAlD
Afatinib—ABL1—renal system—uterine cancer	0.000625	0.00897	CbGeAlD
Afatinib—ABL1—endometrium—uterine cancer	0.000604	0.00867	CbGeAlD
Afatinib—EGFR—lymph node—uterine cancer	0.000593	0.0085	CbGeAlD
Afatinib—ABL1—mammalian vulva—uterine cancer	0.000585	0.00839	CbGeAlD
Afatinib—Upper respiratory tract infection—Progesterone—uterine cancer	0.000562	0.00726	CcSEcCtD
Afatinib—Alanine aminotransferase increased—Medroxyprogesterone Acetate—uterine cancer	0.000559	0.00722	CcSEcCtD
Afatinib—ABL1—uterus—uterine cancer	0.000557	0.00799	CbGeAlD
Afatinib—Weight decreased—Progesterone—uterine cancer	0.000547	0.00706	CcSEcCtD
Afatinib—Aphthous stomatitis—Doxorubicin—uterine cancer	0.000546	0.00704	CcSEcCtD
Afatinib—Pneumonia—Progesterone—uterine cancer	0.000543	0.007	CcSEcCtD
Afatinib—ABCG2—myometrium—uterine cancer	0.000542	0.00777	CbGeAlD
Afatinib—Infestation NOS—Progesterone—uterine cancer	0.000539	0.00696	CcSEcCtD
Afatinib—Infestation—Progesterone—uterine cancer	0.000539	0.00696	CcSEcCtD
Afatinib—Conjunctivitis—Progesterone—uterine cancer	0.000524	0.00677	CcSEcCtD
Afatinib—Urinary tract infection—Progesterone—uterine cancer	0.000524	0.00677	CcSEcCtD
Afatinib—IRAK1—lymph node—uterine cancer	0.000523	0.0075	CbGeAlD
Afatinib—Body temperature increased—Carboplatin—uterine cancer	0.000518	0.00668	CcSEcCtD
Afatinib—Hepatobiliary disease—Progesterone—uterine cancer	0.00051	0.00658	CcSEcCtD
Afatinib—LCK—lymph node—uterine cancer	0.00051	0.00732	CbGeAlD
Afatinib—Upper respiratory tract infection—Medroxyprogesterone Acetate—uterine cancer	0.000509	0.00658	CcSEcCtD
Afatinib—ABL1—female reproductive system—uterine cancer	0.000501	0.00718	CbGeAlD
Afatinib—Mucosal inflammation—Epirubicin—uterine cancer	0.000499	0.00645	CcSEcCtD
Afatinib—Weight decreased—Medroxyprogesterone Acetate—uterine cancer	0.000496	0.0064	CcSEcCtD
Afatinib—Infestation NOS—Medroxyprogesterone Acetate—uterine cancer	0.000489	0.00631	CcSEcCtD
Afatinib—Infestation—Medroxyprogesterone Acetate—uterine cancer	0.000489	0.00631	CcSEcCtD
Afatinib—Urinary tract disorder—Progesterone—uterine cancer	0.000478	0.00617	CcSEcCtD
Afatinib—Stomatitis—Medroxyprogesterone Acetate—uterine cancer	0.000476	0.00615	CcSEcCtD
Afatinib—Connective tissue disorder—Progesterone—uterine cancer	0.000476	0.00614	CcSEcCtD
Afatinib—Urinary tract infection—Medroxyprogesterone Acetate—uterine cancer	0.000475	0.00613	CcSEcCtD
Afatinib—Urethral disorder—Progesterone—uterine cancer	0.000475	0.00613	CcSEcCtD
Afatinib—Hepatobiliary disease—Medroxyprogesterone Acetate—uterine cancer	0.000462	0.00597	CcSEcCtD
Afatinib—Mucosal inflammation—Doxorubicin—uterine cancer	0.000462	0.00596	CcSEcCtD
Afatinib—Epistaxis—Medroxyprogesterone Acetate—uterine cancer	0.000461	0.00595	CcSEcCtD
Afatinib—ERBB2—Podofilox—Etoposide—uterine cancer	0.00046	0.117	CbGdCrCtD
Afatinib—ABL1—female gonad—uterine cancer	0.000456	0.00654	CbGeAlD
Afatinib—ABL1—vagina—uterine cancer	0.000453	0.0065	CbGeAlD
Afatinib—Eye disorder—Progesterone—uterine cancer	0.000453	0.00584	CcSEcCtD
Afatinib—Mouth ulceration—Etoposide—uterine cancer	0.000446	0.00576	CcSEcCtD
Afatinib—Aspartate aminotransferase increased—Dactinomycin—uterine cancer	0.000446	0.00575	CcSEcCtD
Afatinib—Mediastinal disorder—Progesterone—uterine cancer	0.000436	0.00563	CcSEcCtD
Afatinib—Urinary tract disorder—Medroxyprogesterone Acetate—uterine cancer	0.000433	0.00559	CcSEcCtD
Afatinib—Connective tissue disorder—Medroxyprogesterone Acetate—uterine cancer	0.000431	0.00557	CcSEcCtD
Afatinib—Urethral disorder—Medroxyprogesterone Acetate—uterine cancer	0.00043	0.00555	CcSEcCtD
Afatinib—Sepsis—Etoposide—uterine cancer	0.000428	0.00552	CcSEcCtD
Afatinib—Alopecia—Progesterone—uterine cancer	0.000428	0.00552	CcSEcCtD
Afatinib—Keratitis—Epirubicin—uterine cancer	0.000426	0.0055	CcSEcCtD
Afatinib—Mental disorder—Progesterone—uterine cancer	0.000424	0.00548	CcSEcCtD
Afatinib—Malnutrition—Progesterone—uterine cancer	0.000422	0.00544	CcSEcCtD
Afatinib—ABCG2—uterine cervix—uterine cancer	0.000421	0.00605	CbGeAlD
Afatinib—Eye disorder—Medroxyprogesterone Acetate—uterine cancer	0.00041	0.00529	CcSEcCtD
Afatinib—Back pain—Progesterone—uterine cancer	0.000408	0.00526	CcSEcCtD
Afatinib—Muscle spasms—Progesterone—uterine cancer	0.000405	0.00523	CcSEcCtD
Afatinib—ABCG2—decidua—uterine cancer	0.000402	0.00576	CbGeAlD
Afatinib—Mediastinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.000395	0.0051	CcSEcCtD
Afatinib—Keratitis—Doxorubicin—uterine cancer	0.000394	0.00509	CcSEcCtD
Afatinib—Alopecia—Medroxyprogesterone Acetate—uterine cancer	0.000388	0.005	CcSEcCtD
Afatinib—Mental disorder—Medroxyprogesterone Acetate—uterine cancer	0.000384	0.00496	CcSEcCtD
Afatinib—Pneumonia—Dactinomycin—uterine cancer	0.000383	0.00495	CcSEcCtD
Afatinib—Malnutrition—Medroxyprogesterone Acetate—uterine cancer	0.000382	0.00493	CcSEcCtD
Afatinib—ABCG2—endometrium—uterine cancer	0.000381	0.00547	CbGeAlD
Afatinib—Dysgeusia—Medroxyprogesterone Acetate—uterine cancer	0.000374	0.00483	CcSEcCtD
Afatinib—Stomatitis—Dactinomycin—uterine cancer	0.000372	0.0048	CcSEcCtD
Afatinib—Back pain—Medroxyprogesterone Acetate—uterine cancer	0.000369	0.00477	CcSEcCtD
Afatinib—ABCG2—mammalian vulva—uterine cancer	0.000369	0.00529	CbGeAlD
Afatinib—Cough—Progesterone—uterine cancer	0.000368	0.00475	CcSEcCtD
Afatinib—Muscle spasms—Medroxyprogesterone Acetate—uterine cancer	0.000367	0.00474	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Progesterone—uterine cancer	0.000356	0.0046	CcSEcCtD
Afatinib—ABCG2—uterus—uterine cancer	0.000351	0.00504	CbGeAlD
Afatinib—Infection—Progesterone—uterine cancer	0.000342	0.00441	CcSEcCtD
Afatinib—Nervous system disorder—Progesterone—uterine cancer	0.000337	0.00435	CcSEcCtD
Afatinib—Skin disorder—Progesterone—uterine cancer	0.000334	0.00431	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Medroxyprogesterone Acetate—uterine cancer	0.000323	0.00417	CcSEcCtD
Afatinib—Alanine aminotransferase increased—Etoposide—uterine cancer	0.000316	0.00408	CcSEcCtD
Afatinib—DYRK1A—Doxorubicin—Epirubicin—uterine cancer	0.000312	0.0794	CbGdCrCtD
Afatinib—DYRK1A—Idarubicin—Epirubicin—uterine cancer	0.000312	0.0794	CbGdCrCtD
Afatinib—DYRK1A—Daunorubicin—Epirubicin—uterine cancer	0.000312	0.0794	CbGdCrCtD
Afatinib—Insomnia—Progesterone—uterine cancer	0.000311	0.00402	CcSEcCtD
Afatinib—Infection—Medroxyprogesterone Acetate—uterine cancer	0.00031	0.004	CcSEcCtD
Afatinib—Dyspnoea—Progesterone—uterine cancer	0.000307	0.00396	CcSEcCtD
Afatinib—Nervous system disorder—Medroxyprogesterone Acetate—uterine cancer	0.000306	0.00395	CcSEcCtD
Afatinib—Dyspepsia—Progesterone—uterine cancer	0.000303	0.00391	CcSEcCtD
Afatinib—Skin disorder—Medroxyprogesterone Acetate—uterine cancer	0.000303	0.00391	CcSEcCtD
Afatinib—Alopecia—Dactinomycin—uterine cancer	0.000302	0.0039	CcSEcCtD
Afatinib—Decreased appetite—Progesterone—uterine cancer	0.000299	0.00386	CcSEcCtD
Afatinib—Gastrointestinal disorder—Progesterone—uterine cancer	0.000297	0.00383	CcSEcCtD
Afatinib—Fatigue—Progesterone—uterine cancer	0.000297	0.00383	CcSEcCtD
Afatinib—Constipation—Progesterone—uterine cancer	0.000294	0.0038	CcSEcCtD
Afatinib—ABL1—lymph node—uterine cancer	0.000293	0.0042	CbGeAlD
Afatinib—DYRK1A—Epirubicin—Doxorubicin—uterine cancer	0.000289	0.0735	CbGdCrCtD
Afatinib—DYRK1A—Idarubicin—Doxorubicin—uterine cancer	0.000289	0.0735	CbGdCrCtD
Afatinib—DYRK1A—Daunorubicin—Doxorubicin—uterine cancer	0.000289	0.0735	CbGdCrCtD
Afatinib—ABCG2—female gonad—uterine cancer	0.000287	0.00412	CbGeAlD
Afatinib—ABCG2—vagina—uterine cancer	0.000286	0.0041	CbGeAlD
Afatinib—Insomnia—Medroxyprogesterone Acetate—uterine cancer	0.000282	0.00364	CcSEcCtD
Afatinib—Dyspnoea—Medroxyprogesterone Acetate—uterine cancer	0.000278	0.00359	CcSEcCtD
Afatinib—Pneumonia—Etoposide—uterine cancer	0.000278	0.00358	CcSEcCtD
Afatinib—Infestation—Etoposide—uterine cancer	0.000276	0.00356	CcSEcCtD
Afatinib—Infestation NOS—Etoposide—uterine cancer	0.000276	0.00356	CcSEcCtD
Afatinib—Dyspepsia—Medroxyprogesterone Acetate—uterine cancer	0.000274	0.00354	CcSEcCtD
Afatinib—Body temperature increased—Progesterone—uterine cancer	0.000272	0.00351	CcSEcCtD
Afatinib—Renal failure—Etoposide—uterine cancer	0.000271	0.0035	CcSEcCtD
Afatinib—Decreased appetite—Medroxyprogesterone Acetate—uterine cancer	0.000271	0.0035	CcSEcCtD
Afatinib—Cystitis noninfective—Epirubicin—uterine cancer	0.00027	0.00349	CcSEcCtD
Afatinib—Gastrointestinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.000269	0.00347	CcSEcCtD
Afatinib—Stomatitis—Etoposide—uterine cancer	0.000269	0.00347	CcSEcCtD
Afatinib—Fatigue—Medroxyprogesterone Acetate—uterine cancer	0.000269	0.00347	CcSEcCtD
Afatinib—ABCB1—myometrium—uterine cancer	0.000267	0.00383	CbGeAlD
Afatinib—Cystitis—Epirubicin—uterine cancer	0.000267	0.00345	CcSEcCtD
Afatinib—Constipation—Medroxyprogesterone Acetate—uterine cancer	0.000267	0.00344	CcSEcCtD
Afatinib—Hepatobiliary disease—Etoposide—uterine cancer	0.000261	0.00337	CcSEcCtD
Afatinib—Dry eye—Epirubicin—uterine cancer	0.000255	0.0033	CcSEcCtD
Afatinib—Mouth ulceration—Epirubicin—uterine cancer	0.00025	0.00323	CcSEcCtD
Afatinib—Bladder pain—Epirubicin—uterine cancer	0.00025	0.00323	CcSEcCtD
Afatinib—Cystitis noninfective—Doxorubicin—uterine cancer	0.00025	0.00323	CcSEcCtD
Afatinib—Cystitis—Doxorubicin—uterine cancer	0.000247	0.00319	CcSEcCtD
Afatinib—Asthenia—Progesterone—uterine cancer	0.000247	0.00319	CcSEcCtD
Afatinib—Body temperature increased—Medroxyprogesterone Acetate—uterine cancer	0.000246	0.00318	CcSEcCtD
Afatinib—Urinary tract disorder—Etoposide—uterine cancer	0.000245	0.00316	CcSEcCtD
Afatinib—Pruritus—Progesterone—uterine cancer	0.000243	0.00314	CcSEcCtD
Afatinib—Urethral disorder—Etoposide—uterine cancer	0.000243	0.00313	CcSEcCtD
Afatinib—Infection—Dactinomycin—uterine cancer	0.000242	0.00312	CcSEcCtD
Afatinib—ERBB2—Doxorubicin—Epirubicin—uterine cancer	0.00024	0.0611	CbGdCrCtD
Afatinib—Sepsis—Epirubicin—uterine cancer	0.00024	0.0031	CcSEcCtD
Afatinib—Dry eye—Doxorubicin—uterine cancer	0.000236	0.00305	CcSEcCtD
Afatinib—Diarrhoea—Progesterone—uterine cancer	0.000235	0.00304	CcSEcCtD
Afatinib—Eye disorder—Etoposide—uterine cancer	0.000231	0.00299	CcSEcCtD
Afatinib—Mouth ulceration—Doxorubicin—uterine cancer	0.000231	0.00299	CcSEcCtD
Afatinib—Bladder pain—Doxorubicin—uterine cancer	0.000231	0.00299	CcSEcCtD
Afatinib—Dizziness—Progesterone—uterine cancer	0.000227	0.00294	CcSEcCtD
Afatinib—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.000224	0.00289	CcSEcCtD
Afatinib—Mediastinal disorder—Etoposide—uterine cancer	0.000223	0.00288	CcSEcCtD
Afatinib—ERBB2—Epirubicin—Doxorubicin—uterine cancer	0.000222	0.0565	CbGdCrCtD
Afatinib—Sepsis—Doxorubicin—uterine cancer	0.000222	0.00287	CcSEcCtD
Afatinib—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.000221	0.00285	CcSEcCtD
Afatinib—Alopecia—Etoposide—uterine cancer	0.000219	0.00283	CcSEcCtD
Afatinib—Vomiting—Progesterone—uterine cancer	0.000219	0.00282	CcSEcCtD
Afatinib—Rash—Progesterone—uterine cancer	0.000217	0.0028	CcSEcCtD
Afatinib—Dermatitis—Progesterone—uterine cancer	0.000217	0.0028	CcSEcCtD
Afatinib—Headache—Progesterone—uterine cancer	0.000216	0.00278	CcSEcCtD
Afatinib—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.000213	0.00275	CcSEcCtD
Afatinib—Decreased appetite—Dactinomycin—uterine cancer	0.000211	0.00273	CcSEcCtD
Afatinib—Dysgeusia—Etoposide—uterine cancer	0.000211	0.00273	CcSEcCtD
Afatinib—Renal impairment—Epirubicin—uterine cancer	0.000211	0.00272	CcSEcCtD
Afatinib—Fatigue—Dactinomycin—uterine cancer	0.00021	0.00271	CcSEcCtD
Afatinib—ABCB1—epithelium—uterine cancer	0.00021	0.00301	CbGeAlD
Afatinib—Back pain—Etoposide—uterine cancer	0.000209	0.00269	CcSEcCtD
Afatinib—ABCB1—uterine cervix—uterine cancer	0.000208	0.00298	CbGeAlD
Afatinib—Muscle spasms—Etoposide—uterine cancer	0.000207	0.00268	CcSEcCtD
Afatinib—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.000206	0.00266	CcSEcCtD
Afatinib—Nausea—Progesterone—uterine cancer	0.000204	0.00264	CcSEcCtD
Afatinib—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.000198	0.00256	CcSEcCtD
Afatinib—ABCB1—decidua—uterine cancer	0.000198	0.00284	CbGeAlD
Afatinib—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000197	0.00254	CcSEcCtD
Afatinib—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000196	0.00253	CcSEcCtD
Afatinib—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000195	0.00252	CcSEcCtD
Afatinib—Renal impairment—Doxorubicin—uterine cancer	0.000195	0.00252	CcSEcCtD
Afatinib—ABCB1—renal system—uterine cancer	0.000194	0.00279	CbGeAlD
Afatinib—Body temperature increased—Dactinomycin—uterine cancer	0.000192	0.00248	CcSEcCtD
Afatinib—Cough—Etoposide—uterine cancer	0.000188	0.00243	CcSEcCtD
Afatinib—ABCB1—endometrium—uterine cancer	0.000188	0.0027	CbGeAlD
Afatinib—Dehydration—Epirubicin—uterine cancer	0.000187	0.00241	CcSEcCtD
Afatinib—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000185	0.00239	CcSEcCtD
Afatinib—ABCG2—lymph node—uterine cancer	0.000185	0.00265	CbGeAlD
Afatinib—Dry skin—Epirubicin—uterine cancer	0.000184	0.00237	CcSEcCtD
Afatinib—Hypokalaemia—Epirubicin—uterine cancer	0.000183	0.00236	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.000182	0.00235	CcSEcCtD
Afatinib—ABCB1—mammalian vulva—uterine cancer	0.000182	0.00261	CbGeAlD
Afatinib—Aspartate aminotransferase increased—Epirubicin—uterine cancer	0.000181	0.00233	CcSEcCtD
Afatinib—Nasopharyngitis—Epirubicin—uterine cancer	0.000179	0.00232	CcSEcCtD
Afatinib—ABL1—Daunorubicin—Epirubicin—uterine cancer	0.000179	0.0456	CbGdCrCtD
Afatinib—ABL1—Idarubicin—Epirubicin—uterine cancer	0.000179	0.0456	CbGdCrCtD
Afatinib—ABL1—Doxorubicin—Epirubicin—uterine cancer	0.000179	0.0456	CbGdCrCtD
Afatinib—Alanine aminotransferase increased—Epirubicin—uterine cancer	0.000177	0.00228	CcSEcCtD
Afatinib—Infection—Etoposide—uterine cancer	0.000175	0.00226	CcSEcCtD
Afatinib—Asthenia—Dactinomycin—uterine cancer	0.000174	0.00225	CcSEcCtD
Afatinib—ABCB1—uterus—uterine cancer	0.000173	0.00249	CbGeAlD
Afatinib—Dehydration—Doxorubicin—uterine cancer	0.000173	0.00223	CcSEcCtD
Afatinib—Skin disorder—Etoposide—uterine cancer	0.000171	0.00221	CcSEcCtD
Afatinib—Dry skin—Doxorubicin—uterine cancer	0.00017	0.0022	CcSEcCtD
Afatinib—ERBB2—Levonorgestrel—Progesterone—uterine cancer	0.00017	0.0432	CbGdCrCtD
Afatinib—Hypokalaemia—Doxorubicin—uterine cancer	0.000169	0.00218	CcSEcCtD
Afatinib—Aspartate aminotransferase increased—Doxorubicin—uterine cancer	0.000167	0.00216	CcSEcCtD
Afatinib—Diarrhoea—Dactinomycin—uterine cancer	0.000166	0.00215	CcSEcCtD
Afatinib—Nasopharyngitis—Doxorubicin—uterine cancer	0.000166	0.00214	CcSEcCtD
Afatinib—ABL1—Daunorubicin—Doxorubicin—uterine cancer	0.000166	0.0422	CbGdCrCtD
Afatinib—ABL1—Epirubicin—Doxorubicin—uterine cancer	0.000166	0.0422	CbGdCrCtD
Afatinib—ABL1—Idarubicin—Doxorubicin—uterine cancer	0.000166	0.0422	CbGdCrCtD
Afatinib—Alanine aminotransferase increased—Doxorubicin—uterine cancer	0.000164	0.00211	CcSEcCtD
Afatinib—Upper respiratory tract infection—Epirubicin—uterine cancer	0.000161	0.00208	CcSEcCtD
Afatinib—Weight decreased—Epirubicin—uterine cancer	0.000157	0.00203	CcSEcCtD
Afatinib—Dyspnoea—Etoposide—uterine cancer	0.000157	0.00203	CcSEcCtD
Afatinib—ABCB1—female reproductive system—uterine cancer	0.000156	0.00223	CbGeAlD
Afatinib—Pneumonia—Epirubicin—uterine cancer	0.000156	0.00201	CcSEcCtD
Afatinib—Infestation—Epirubicin—uterine cancer	0.000155	0.002	CcSEcCtD
Afatinib—Infestation NOS—Epirubicin—uterine cancer	0.000155	0.002	CcSEcCtD
Afatinib—Vomiting—Dactinomycin—uterine cancer	0.000155	0.002	CcSEcCtD
Afatinib—Rash—Dactinomycin—uterine cancer	0.000153	0.00198	CcSEcCtD
Afatinib—Decreased appetite—Etoposide—uterine cancer	0.000153	0.00197	CcSEcCtD
Afatinib—Renal failure—Epirubicin—uterine cancer	0.000152	0.00196	CcSEcCtD
Afatinib—Gastrointestinal disorder—Etoposide—uterine cancer	0.000152	0.00196	CcSEcCtD
Afatinib—Fatigue—Etoposide—uterine cancer	0.000152	0.00196	CcSEcCtD
Afatinib—Stomatitis—Epirubicin—uterine cancer	0.000151	0.00195	CcSEcCtD
Afatinib—Constipation—Etoposide—uterine cancer	0.00015	0.00194	CcSEcCtD
Afatinib—Urinary tract infection—Epirubicin—uterine cancer	0.00015	0.00194	CcSEcCtD
Afatinib—Conjunctivitis—Epirubicin—uterine cancer	0.00015	0.00194	CcSEcCtD
Afatinib—Upper respiratory tract infection—Doxorubicin—uterine cancer	0.000149	0.00193	CcSEcCtD
Afatinib—Hepatobiliary disease—Epirubicin—uterine cancer	0.000146	0.00189	CcSEcCtD
Afatinib—Epistaxis—Epirubicin—uterine cancer	0.000146	0.00188	CcSEcCtD
Afatinib—Weight decreased—Doxorubicin—uterine cancer	0.000145	0.00187	CcSEcCtD
Afatinib—Nausea—Dactinomycin—uterine cancer	0.000144	0.00186	CcSEcCtD
Afatinib—Pneumonia—Doxorubicin—uterine cancer	0.000144	0.00186	CcSEcCtD
Afatinib—Infestation—Doxorubicin—uterine cancer	0.000143	0.00185	CcSEcCtD
Afatinib—Infestation NOS—Doxorubicin—uterine cancer	0.000143	0.00185	CcSEcCtD
Afatinib—ABCB1—female gonad—uterine cancer	0.000142	0.00203	CbGeAlD
Afatinib—ABCB1—vagina—uterine cancer	0.000141	0.00202	CbGeAlD
Afatinib—Renal failure—Doxorubicin—uterine cancer	0.000141	0.00182	CcSEcCtD
Afatinib—Stomatitis—Doxorubicin—uterine cancer	0.00014	0.0018	CcSEcCtD
Afatinib—Body temperature increased—Etoposide—uterine cancer	0.000139	0.0018	CcSEcCtD
Afatinib—Conjunctivitis—Doxorubicin—uterine cancer	0.000139	0.0018	CcSEcCtD
Afatinib—Urinary tract infection—Doxorubicin—uterine cancer	0.000139	0.0018	CcSEcCtD
Afatinib—Urinary tract disorder—Epirubicin—uterine cancer	0.000137	0.00177	CcSEcCtD
Afatinib—Connective tissue disorder—Epirubicin—uterine cancer	0.000136	0.00176	CcSEcCtD
Afatinib—Urethral disorder—Epirubicin—uterine cancer	0.000136	0.00176	CcSEcCtD
Afatinib—Hepatobiliary disease—Doxorubicin—uterine cancer	0.000135	0.00175	CcSEcCtD
Afatinib—Epistaxis—Doxorubicin—uterine cancer	0.000135	0.00174	CcSEcCtD
Afatinib—Eye disorder—Epirubicin—uterine cancer	0.00013	0.00167	CcSEcCtD
Afatinib—Urinary tract disorder—Doxorubicin—uterine cancer	0.000127	0.00164	CcSEcCtD
Afatinib—Asthenia—Etoposide—uterine cancer	0.000126	0.00163	CcSEcCtD
Afatinib—Connective tissue disorder—Doxorubicin—uterine cancer	0.000126	0.00163	CcSEcCtD
Afatinib—Urethral disorder—Doxorubicin—uterine cancer	0.000126	0.00163	CcSEcCtD
Afatinib—Mediastinal disorder—Epirubicin—uterine cancer	0.000125	0.00162	CcSEcCtD
Afatinib—Pruritus—Etoposide—uterine cancer	0.000125	0.00161	CcSEcCtD
Afatinib—Alopecia—Epirubicin—uterine cancer	0.000123	0.00158	CcSEcCtD
Afatinib—Mental disorder—Epirubicin—uterine cancer	0.000122	0.00157	CcSEcCtD
Afatinib—Malnutrition—Epirubicin—uterine cancer	0.000121	0.00156	CcSEcCtD
Afatinib—Diarrhoea—Etoposide—uterine cancer	0.00012	0.00155	CcSEcCtD
Afatinib—Eye disorder—Doxorubicin—uterine cancer	0.00012	0.00155	CcSEcCtD
Afatinib—Dysgeusia—Epirubicin—uterine cancer	0.000118	0.00153	CcSEcCtD
Afatinib—Back pain—Epirubicin—uterine cancer	0.000117	0.00151	CcSEcCtD
Afatinib—Dizziness—Etoposide—uterine cancer	0.000116	0.0015	CcSEcCtD
Afatinib—Muscle spasms—Epirubicin—uterine cancer	0.000116	0.0015	CcSEcCtD
Afatinib—Mediastinal disorder—Doxorubicin—uterine cancer	0.000116	0.00149	CcSEcCtD
Afatinib—Alopecia—Doxorubicin—uterine cancer	0.000114	0.00147	CcSEcCtD
Afatinib—Mental disorder—Doxorubicin—uterine cancer	0.000113	0.00145	CcSEcCtD
Afatinib—Vomiting—Etoposide—uterine cancer	0.000112	0.00144	CcSEcCtD
Afatinib—Malnutrition—Doxorubicin—uterine cancer	0.000112	0.00144	CcSEcCtD
Afatinib—Rash—Etoposide—uterine cancer	0.000111	0.00143	CcSEcCtD
Afatinib—Dermatitis—Etoposide—uterine cancer	0.000111	0.00143	CcSEcCtD
Afatinib—Headache—Etoposide—uterine cancer	0.00011	0.00142	CcSEcCtD
Afatinib—Dysgeusia—Doxorubicin—uterine cancer	0.00011	0.00141	CcSEcCtD
Afatinib—Back pain—Doxorubicin—uterine cancer	0.000108	0.0014	CcSEcCtD
Afatinib—Muscle spasms—Doxorubicin—uterine cancer	0.000108	0.00139	CcSEcCtD
Afatinib—Cough—Epirubicin—uterine cancer	0.000105	0.00136	CcSEcCtD
Afatinib—Nausea—Etoposide—uterine cancer	0.000105	0.00135	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.000102	0.00132	CcSEcCtD
Afatinib—Infection—Epirubicin—uterine cancer	9.8e-05	0.00126	CcSEcCtD
Afatinib—Cough—Doxorubicin—uterine cancer	9.76e-05	0.00126	CcSEcCtD
Afatinib—Nervous system disorder—Epirubicin—uterine cancer	9.67e-05	0.00125	CcSEcCtD
Afatinib—Skin disorder—Epirubicin—uterine cancer	9.58e-05	0.00124	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	9.46e-05	0.00122	CcSEcCtD
Afatinib—ABCB1—lymph node—uterine cancer	9.11e-05	0.00131	CbGeAlD
Afatinib—Infection—Doxorubicin—uterine cancer	9.07e-05	0.00117	CcSEcCtD
Afatinib—Nervous system disorder—Doxorubicin—uterine cancer	8.95e-05	0.00116	CcSEcCtD
Afatinib—Insomnia—Epirubicin—uterine cancer	8.92e-05	0.00115	CcSEcCtD
Afatinib—Skin disorder—Doxorubicin—uterine cancer	8.87e-05	0.00114	CcSEcCtD
Afatinib—Dyspnoea—Epirubicin—uterine cancer	8.8e-05	0.00114	CcSEcCtD
Afatinib—Dyspepsia—Epirubicin—uterine cancer	8.68e-05	0.00112	CcSEcCtD
Afatinib—Decreased appetite—Epirubicin—uterine cancer	8.58e-05	0.00111	CcSEcCtD
Afatinib—Gastrointestinal disorder—Epirubicin—uterine cancer	8.52e-05	0.0011	CcSEcCtD
Afatinib—Fatigue—Epirubicin—uterine cancer	8.51e-05	0.0011	CcSEcCtD
Afatinib—Constipation—Epirubicin—uterine cancer	8.44e-05	0.00109	CcSEcCtD
Afatinib—Insomnia—Doxorubicin—uterine cancer	8.26e-05	0.00107	CcSEcCtD
Afatinib—Dyspnoea—Doxorubicin—uterine cancer	8.14e-05	0.00105	CcSEcCtD
Afatinib—Dyspepsia—Doxorubicin—uterine cancer	8.03e-05	0.00104	CcSEcCtD
Afatinib—Decreased appetite—Doxorubicin—uterine cancer	7.93e-05	0.00102	CcSEcCtD
Afatinib—Gastrointestinal disorder—Doxorubicin—uterine cancer	7.88e-05	0.00102	CcSEcCtD
Afatinib—Fatigue—Doxorubicin—uterine cancer	7.87e-05	0.00102	CcSEcCtD
Afatinib—Constipation—Doxorubicin—uterine cancer	7.81e-05	0.00101	CcSEcCtD
Afatinib—Body temperature increased—Epirubicin—uterine cancer	7.8e-05	0.00101	CcSEcCtD
Afatinib—Body temperature increased—Doxorubicin—uterine cancer	7.22e-05	0.000931	CcSEcCtD
Afatinib—Asthenia—Epirubicin—uterine cancer	7.08e-05	0.000914	CcSEcCtD
Afatinib—Pruritus—Epirubicin—uterine cancer	6.98e-05	0.000901	CcSEcCtD
Afatinib—Diarrhoea—Epirubicin—uterine cancer	6.75e-05	0.000871	CcSEcCtD
Afatinib—Asthenia—Doxorubicin—uterine cancer	6.55e-05	0.000845	CcSEcCtD
Afatinib—Dizziness—Epirubicin—uterine cancer	6.52e-05	0.000842	CcSEcCtD
Afatinib—Pruritus—Doxorubicin—uterine cancer	6.46e-05	0.000833	CcSEcCtD
Afatinib—Vomiting—Epirubicin—uterine cancer	6.27e-05	0.00081	CcSEcCtD
Afatinib—Diarrhoea—Doxorubicin—uterine cancer	6.25e-05	0.000806	CcSEcCtD
Afatinib—Rash—Epirubicin—uterine cancer	6.22e-05	0.000803	CcSEcCtD
Afatinib—Dermatitis—Epirubicin—uterine cancer	6.21e-05	0.000802	CcSEcCtD
Afatinib—Headache—Epirubicin—uterine cancer	6.18e-05	0.000798	CcSEcCtD
Afatinib—Dizziness—Doxorubicin—uterine cancer	6.04e-05	0.000779	CcSEcCtD
Afatinib—Nausea—Epirubicin—uterine cancer	5.86e-05	0.000756	CcSEcCtD
Afatinib—Vomiting—Doxorubicin—uterine cancer	5.8e-05	0.000749	CcSEcCtD
Afatinib—Rash—Doxorubicin—uterine cancer	5.76e-05	0.000743	CcSEcCtD
Afatinib—Dermatitis—Doxorubicin—uterine cancer	5.75e-05	0.000742	CcSEcCtD
Afatinib—Headache—Doxorubicin—uterine cancer	5.72e-05	0.000738	CcSEcCtD
Afatinib—Nausea—Doxorubicin—uterine cancer	5.42e-05	0.0007	CcSEcCtD
Afatinib—EGFR—Innate Immune System—PTEN—uterine cancer	9.84e-06	8.51e-05	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—KRAS—uterine cancer	9.83e-06	8.5e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—FBXW7—uterine cancer	9.78e-06	8.45e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—NRAS—uterine cancer	9.77e-06	8.45e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—CTNNB1—uterine cancer	9.73e-06	8.42e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—NRAS—uterine cancer	9.62e-06	8.32e-05	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—HRAS—uterine cancer	9.61e-06	8.31e-05	CbGpPWpGaD
Afatinib—LCK—Signaling by NGF—AKT1—uterine cancer	9.59e-06	8.29e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—POLD1—uterine cancer	9.54e-06	8.25e-05	CbGpPWpGaD
Afatinib—LCK—Disease—FGFR2—uterine cancer	9.53e-06	8.24e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—VEGFA—uterine cancer	9.52e-06	8.23e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—MTHFR—uterine cancer	9.52e-06	8.23e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—PTEN—uterine cancer	9.49e-06	8.2e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—PTEN—uterine cancer	9.45e-06	8.17e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—NRAS—uterine cancer	9.4e-06	8.13e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—EP300—uterine cancer	9.39e-06	8.12e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—CDH1—uterine cancer	9.33e-06	8.06e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—CDKN1B—uterine cancer	9.31e-06	8.05e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	9.24e-06	7.99e-05	CbGpPWpGaD
Afatinib—LCK—Disease—MTHFR—uterine cancer	9.17e-06	7.93e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—PTEN—uterine cancer	9.11e-06	7.88e-05	CbGpPWpGaD
Afatinib—ERBB2—Immune System—KRAS—uterine cancer	9.11e-06	7.87e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—EP300—uterine cancer	9.05e-06	7.82e-05	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—PIK3CA—uterine cancer	9.03e-06	7.81e-05	CbGpPWpGaD
Afatinib—ERBB4—Immune System—KRAS—uterine cancer	8.97e-06	7.76e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—AKR1C1—uterine cancer	8.93e-06	7.72e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—STK11—uterine cancer	8.87e-06	7.67e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—ERBB2—uterine cancer	8.86e-06	7.66e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—ESR1—uterine cancer	8.86e-06	7.66e-05	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—KRAS—uterine cancer	8.85e-06	7.65e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—CCL2—uterine cancer	8.83e-06	7.63e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—CTNNB1—uterine cancer	8.8e-06	7.61e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—NRAS—uterine cancer	8.78e-06	7.59e-05	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—TP53—uterine cancer	8.73e-06	7.55e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—KRAS—uterine cancer	8.63e-06	7.46e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—PTEN—uterine cancer	8.58e-06	7.41e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—KRAS—uterine cancer	8.56e-06	7.4e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—STK11—uterine cancer	8.55e-06	7.39e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—CXCL8—uterine cancer	8.53e-06	7.37e-05	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—HRAS—uterine cancer	8.51e-06	7.36e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	8.49e-06	7.34e-05	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—AKT1—uterine cancer	8.48e-06	7.34e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—NRAS—uterine cancer	8.46e-06	7.32e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—NRAS—uterine cancer	8.43e-06	7.29e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—KRAS—uterine cancer	8.41e-06	7.27e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—CXCL8—uterine cancer	8.4e-06	7.26e-05	CbGpPWpGaD
Afatinib—ERBB2—Immune System—PIK3CA—uterine cancer	8.37e-06	7.23e-05	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—HRAS—uterine cancer	8.35e-06	7.22e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—CDKN1B—uterine cancer	8.33e-06	7.2e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—SOCS3—uterine cancer	8.3e-06	7.18e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—KRAS—uterine cancer	8.28e-06	7.16e-05	CbGpPWpGaD
Afatinib—ERBB4—Immune System—PIK3CA—uterine cancer	8.24e-06	7.13e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	8.21e-06	7.1e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—CDKN1B—uterine cancer	8.2e-06	7.09e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—EP300—uterine cancer	8.18e-06	7.07e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—NRAS—uterine cancer	8.13e-06	7.03e-05	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—PIK3CA—uterine cancer	8.13e-06	7.03e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—KRAS—uterine cancer	8.09e-06	7e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—SOCS3—uterine cancer	8e-06	6.92e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—CDH1—uterine cancer	7.97e-06	6.89e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—RRM2—uterine cancer	7.96e-06	6.88e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CDKN2B—uterine cancer	7.95e-06	6.87e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—PIK3CA—uterine cancer	7.93e-06	6.85e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—ERBB2—uterine cancer	7.87e-06	6.8e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—CTNNB1—uterine cancer	7.87e-06	6.8e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CCL2—uterine cancer	7.8e-06	6.74e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—CTNNB1—uterine cancer	7.75e-06	6.7e-05	CbGpPWpGaD
Afatinib—ERBB2—Immune System—HRAS—uterine cancer	7.74e-06	6.69e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—PIK3CA—uterine cancer	7.73e-06	6.68e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—DCN—uterine cancer	7.72e-06	6.68e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IGF1R—uterine cancer	7.72e-06	6.67e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—CDH1—uterine cancer	7.68e-06	6.64e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—PTEN—uterine cancer	7.67e-06	6.63e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CDKN2B—uterine cancer	7.66e-06	6.62e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—NRAS—uterine cancer	7.65e-06	6.61e-05	CbGpPWpGaD
Afatinib—ERBB4—Immune System—HRAS—uterine cancer	7.63e-06	6.59e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—PIK3CA—uterine cancer	7.61e-06	6.58e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—KRAS—uterine cancer	7.56e-06	6.54e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—PTEN—uterine cancer	7.55e-06	6.53e-05	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—HRAS—uterine cancer	7.52e-06	6.5e-05	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—AKT1—uterine cancer	7.52e-06	6.5e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—MTHFR—uterine cancer	7.44e-06	6.43e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IGF1R—uterine cancer	7.44e-06	6.43e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—PIK3CA—uterine cancer	7.43e-06	6.43e-05	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—AKT1—uterine cancer	7.37e-06	6.38e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—HRAS—uterine cancer	7.34e-06	6.34e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—EP300—uterine cancer	7.31e-06	6.32e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—CDKN1B—uterine cancer	7.29e-06	6.3e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—KRAS—uterine cancer	7.28e-06	6.3e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CYP11A1—uterine cancer	7.28e-06	6.29e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—HRAS—uterine cancer	7.28e-06	6.29e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—KRAS—uterine cancer	7.26e-06	6.28e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—SMAD3—uterine cancer	7.26e-06	6.28e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—EP300—uterine cancer	7.2e-06	6.23e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—TP53—uterine cancer	7.19e-06	6.22e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—HRAS—uterine cancer	7.15e-06	6.18e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—HRAS—uterine cancer	7.04e-06	6.09e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—KRAS—uterine cancer	7e-06	6.05e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—SMAD3—uterine cancer	6.99e-06	6.05e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—CXCL8—uterine cancer	6.98e-06	6.03e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—PIK3CA—uterine cancer	6.95e-06	6e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	6.93e-06	6e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—VEGFA—uterine cancer	6.93e-06	5.99e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—FGFR2—uterine cancer	6.92e-06	5.99e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—CTNNB1—uterine cancer	6.88e-06	5.95e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—HRAS—uterine cancer	6.88e-06	5.95e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—AKR1C3—uterine cancer	6.87e-06	5.94e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—NRAS—uterine cancer	6.84e-06	5.92e-05	CbGpPWpGaD
Afatinib—ERBB2—Immune System—AKT1—uterine cancer	6.84e-06	5.91e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—VEGFA—uterine cancer	6.82e-06	5.9e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—NRAS—uterine cancer	6.74e-06	5.83e-05	CbGpPWpGaD
Afatinib—ERBB4—Immune System—AKT1—uterine cancer	6.73e-06	5.82e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—ERBB2—uterine cancer	6.72e-06	5.81e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—PTEN—uterine cancer	6.71e-06	5.8e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—PIK3CA—uterine cancer	6.69e-06	5.79e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—FGFR2—uterine cancer	6.67e-06	5.77e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—PIK3CA—uterine cancer	6.67e-06	5.77e-05	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—AKT1—uterine cancer	6.64e-06	5.74e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—KRAS—uterine cancer	6.58e-06	5.69e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—ERBB2—uterine cancer	6.5e-06	5.62e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—ERBB2—uterine cancer	6.48e-06	5.6e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—AKT1—uterine cancer	6.48e-06	5.6e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—PIK3CA—uterine cancer	6.43e-06	5.56e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—HRAS—uterine cancer	6.43e-06	5.56e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—AKT1—uterine cancer	6.42e-06	5.55e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—EP300—uterine cancer	6.4e-06	5.53e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—AKT1—uterine cancer	6.31e-06	5.46e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—CDKN1B—uterine cancer	6.23e-06	5.38e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—AKT1—uterine cancer	6.22e-06	5.37e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—ERBB2—uterine cancer	6.21e-06	5.37e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—HRAS—uterine cancer	6.19e-06	5.35e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—HRAS—uterine cancer	6.17e-06	5.33e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CXCL8—uterine cancer	6.17e-06	5.33e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—AKT1—uterine cancer	6.07e-06	5.25e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—PIK3CA—uterine cancer	6.05e-06	5.23e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CDKN1B—uterine cancer	6.02e-06	5.21e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—CDKN1B—uterine cancer	6e-06	5.19e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—NRAS—uterine cancer	5.99e-06	5.18e-05	CbGpPWpGaD
Afatinib—LCK—Disease—ERBB2—uterine cancer	5.98e-06	5.17e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—HRAS—uterine cancer	5.95e-06	5.14e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—ESR1—uterine cancer	5.92e-06	5.12e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—KRAS—uterine cancer	5.89e-06	5.09e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—CTNNB1—uterine cancer	5.88e-06	5.09e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—KRAS—uterine cancer	5.8e-06	5.01e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—CDKN1B—uterine cancer	5.75e-06	4.97e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—PTEN—uterine cancer	5.73e-06	4.96e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—ESR1—uterine cancer	5.71e-06	4.94e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CTNNB1—uterine cancer	5.69e-06	4.92e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—AKT1—uterine cancer	5.67e-06	4.91e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—CTNNB1—uterine cancer	5.67e-06	4.9e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—NRAS—uterine cancer	5.6e-06	4.84e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—HRAS—uterine cancer	5.6e-06	4.84e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—PTEN—uterine cancer	5.54e-06	4.79e-05	CbGpPWpGaD
Afatinib—LCK—Disease—CDKN1B—uterine cancer	5.54e-06	4.79e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—PTEN—uterine cancer	5.53e-06	4.78e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—EP300—uterine cancer	5.47e-06	4.73e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—AKT1—uterine cancer	5.47e-06	4.73e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—AKT1—uterine cancer	5.45e-06	4.71e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—CTNNB1—uterine cancer	5.43e-06	4.7e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—PIK3CA—uterine cancer	5.41e-06	4.68e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—STK11—uterine cancer	5.35e-06	4.63e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CYP19A1—uterine cancer	5.35e-06	4.63e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—PIK3CA—uterine cancer	5.33e-06	4.61e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—PTEN—uterine cancer	5.29e-06	4.58e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—EP300—uterine cancer	5.29e-06	4.57e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—EP300—uterine cancer	5.27e-06	4.56e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—AKT1—uterine cancer	5.25e-06	4.54e-05	CbGpPWpGaD
Afatinib—LCK—Disease—CTNNB1—uterine cancer	5.23e-06	4.53e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—TP53—uterine cancer	5.23e-06	4.52e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CCL2—uterine cancer	5.21e-06	4.51e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—TP53—uterine cancer	5.16e-06	4.46e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—KRAS—uterine cancer	5.15e-06	4.45e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—NRAS—uterine cancer	5.12e-06	4.42e-05	CbGpPWpGaD
Afatinib—LCK—Disease—PTEN—uterine cancer	5.1e-06	4.41e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—EP300—uterine cancer	5.05e-06	4.37e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CCL2—uterine cancer	5.03e-06	4.34e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—VEGFA—uterine cancer	5.01e-06	4.33e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—HRAS—uterine cancer	5.01e-06	4.33e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—NRAS—uterine cancer	4.95e-06	4.28e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—AKT1—uterine cancer	4.94e-06	4.27e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—HRAS—uterine cancer	4.93e-06	4.26e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—NRAS—uterine cancer	4.93e-06	4.26e-05	CbGpPWpGaD
Afatinib—LCK—Disease—EP300—uterine cancer	4.87e-06	4.21e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—KRAS—uterine cancer	4.82e-06	4.17e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—PIK3CA—uterine cancer	4.73e-06	4.09e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—NRAS—uterine cancer	4.72e-06	4.08e-05	CbGpPWpGaD
Afatinib—LCK—Disease—NRAS—uterine cancer	4.55e-06	3.94e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—PIK3CA—uterine cancer	4.43e-06	3.83e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—AKT1—uterine cancer	4.42e-06	3.82e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—KRAS—uterine cancer	4.4e-06	3.81e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—HRAS—uterine cancer	4.38e-06	3.79e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—AKT1—uterine cancer	4.35e-06	3.76e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—ERBB2—uterine cancer	4.35e-06	3.76e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—KRAS—uterine cancer	4.26e-06	3.68e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—KRAS—uterine cancer	4.24e-06	3.67e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—ERBB2—uterine cancer	4.19e-06	3.62e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PTEN—uterine cancer	4.14e-06	3.58e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CXCL8—uterine cancer	4.12e-06	3.56e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—HRAS—uterine cancer	4.1e-06	3.54e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—KRAS—uterine cancer	4.07e-06	3.51e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—PIK3CA—uterine cancer	4.05e-06	3.5e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CDKN1B—uterine cancer	4.03e-06	3.48e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—MTHFR—uterine cancer	4.02e-06	3.48e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CXCL8—uterine cancer	3.97e-06	3.44e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—EP300—uterine cancer	3.95e-06	3.41e-05	CbGpPWpGaD
Afatinib—LCK—Disease—KRAS—uterine cancer	3.92e-06	3.39e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—PIK3CA—uterine cancer	3.91e-06	3.38e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—PIK3CA—uterine cancer	3.9e-06	3.37e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CDKN1B—uterine cancer	3.88e-06	3.35e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—AKT1—uterine cancer	3.87e-06	3.34e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CTNNB1—uterine cancer	3.8e-06	3.29e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—TP53—uterine cancer	3.78e-06	3.27e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—HRAS—uterine cancer	3.74e-06	3.24e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—PIK3CA—uterine cancer	3.73e-06	3.23e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PTEN—uterine cancer	3.71e-06	3.21e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CTNNB1—uterine cancer	3.67e-06	3.17e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—HRAS—uterine cancer	3.62e-06	3.13e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—AKT1—uterine cancer	3.62e-06	3.13e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—HRAS—uterine cancer	3.61e-06	3.12e-05	CbGpPWpGaD
Afatinib—LCK—Disease—PIK3CA—uterine cancer	3.6e-06	3.11e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PTEN—uterine cancer	3.57e-06	3.09e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—EP300—uterine cancer	3.54e-06	3.06e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—HRAS—uterine cancer	3.46e-06	2.99e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—EP300—uterine cancer	3.41e-06	2.95e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—VEGFA—uterine cancer	3.35e-06	2.9e-05	CbGpPWpGaD
Afatinib—LCK—Disease—HRAS—uterine cancer	3.33e-06	2.88e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—NRAS—uterine cancer	3.31e-06	2.86e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—AKT1—uterine cancer	3.3e-06	2.86e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—VEGFA—uterine cancer	3.23e-06	2.79e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—AKT1—uterine cancer	3.2e-06	2.76e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—NRAS—uterine cancer	3.19e-06	2.76e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—AKT1—uterine cancer	3.18e-06	2.75e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—AKT1—uterine cancer	3.05e-06	2.64e-05	CbGpPWpGaD
Afatinib—LCK—Disease—AKT1—uterine cancer	2.94e-06	2.54e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PIK3CA—uterine cancer	2.92e-06	2.52e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—KRAS—uterine cancer	2.85e-06	2.46e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—KRAS—uterine cancer	2.74e-06	2.37e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PIK3CA—uterine cancer	2.62e-06	2.26e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TP53—uterine cancer	2.53e-06	2.19e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PIK3CA—uterine cancer	2.52e-06	2.18e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TP53—uterine cancer	2.44e-06	2.11e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—HRAS—uterine cancer	2.42e-06	2.09e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—AKT1—uterine cancer	2.39e-06	2.06e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—HRAS—uterine cancer	2.33e-06	2.02e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PTEN—uterine cancer	2.24e-06	1.93e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—AKT1—uterine cancer	2.14e-06	1.85e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—EP300—uterine cancer	2.13e-06	1.85e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—AKT1—uterine cancer	2.06e-06	1.78e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PIK3CA—uterine cancer	1.58e-06	1.36e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—AKT1—uterine cancer	1.29e-06	1.12e-05	CbGpPWpGaD
